TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03727711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPTNS
Description: We will be comparing hospital treatment to TPTNS at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TPTNS
Description: We will be comparing hospital treatment to TPTNS at home
Study: NCT00751881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study: NCT03067558

Intervention type: DIAGNOSTIC_TEST
Intervention: Children's automated respiratory rate monitor
Description: The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities.

Intervention type: DIAGNOSTIC_TEST
Intervention: Children's automated respiratory rate monitor
Description: The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities.

Intervention type: DIAGNOSTIC_TEST
Intervention: MK2 Acute Respiratory Infection (ARI) Timer
Description: The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.

Intervention type: DIAGNOSTIC_TEST
Intervention: MK2 Acute Respiratory Infection (ARI) Timer
Description: The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.

Intervention type: DIAGNOSTIC_TEST
Intervention: MK2 Acute Respiratory Infection (ARI) Timer
Description: The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
Study: NCT02561377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
Study: NCT04534465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
Study: NCT04733443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus
Description: 140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® Please Neo
Description: 140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
Study: NCT03850288

Intervention type: OTHER
Intervention: Neuropsychological assessment : Stroop task
Description: Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive.

Intervention type: OTHER
Intervention: Neuropsychological assessment : Stroop task
Description: Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive.

Intervention type: OTHER
Intervention: Neuropsychological assessment : Stroop task
Description: Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive.

Intervention type: OTHER
Intervention: Neuropsychological assessment : Go No Go task
Description: Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive.

Intervention type: OTHER
Intervention: Neuropsychological assessment : Go No Go task
Description: Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive.

Intervention type: OTHER
Intervention: Neuropsychological assessment : Go No Go task
Description: Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive.
Study: NCT02579928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
Study: NCT01979146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Unrelieved Symptom Alert
Description: The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
Study: NCT05391594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized posture support
Description: We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
Study: NCT02689817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch
Description: A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
Study: NCT04560725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Choline
Description: 11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
Study: NCT03713866

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EP Imaging and Testing
Description: Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation.
Study: NCT04090398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT
Study: NCT02702895

Intervention type: BEHAVIORAL
Intervention: In-depth Interview (IDIs) or Focus Group Discussion (FGD)

Intervention type: BEHAVIORAL
Intervention: In-depth Interview (IDIs) or Focus Group Discussion (FGD)

Intervention type: BEHAVIORAL
Intervention: In-depth Interview (IDIs) or Focus Group Discussion (FGD)
Study: NCT03613038

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Phonetic complexity effects on speech motor performance
Description: Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
Study: NCT01800838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silicon phthalocyanine 4
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01370122

Intervention type: OTHER
Intervention: Survey

Intervention type: OTHER
Intervention: Survey
Study: NCT01458886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 MD
Description: 2 puffs b.i.d. via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: 2 puffs LD b.i.d. via Respimat inhaler
Study: NCT01376882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and Placebo
Description: 100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and Caffeine
Description: Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
Study: NCT01808703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PeriZone PerioPatch
Description: The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing alone
Description: Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing alone
Description: Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
Study: NCT04156646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
Study: NCT01373905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver
Description: group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recruitment maneuver
Description: group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver
Description: recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver
Description: recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
Study: NCT04258553

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia Modified Albumin(IU/mL)
Description: The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ischemia Modified Albumin(IU/mL)
Description: The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
Study: NCT04272125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123 CAR-T cells
Description: A single infusion of CD123-CAR-T cells will be administered intravenously
Study: NCT02572687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Administered IV
Study: NCT04298658

Intervention type: DIAGNOSTIC_TEST
Intervention: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised
Description: Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)

Intervention type: DIAGNOSTIC_TEST
Intervention: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised
Description: Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)

Intervention type: DIAGNOSTIC_TEST
Intervention: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised
Description: Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
Study: NCT03875573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
Study: NCT04298658

Intervention type: DIAGNOSTIC_TEST
Intervention: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised
Description: Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)

Intervention type: DIAGNOSTIC_TEST
Intervention: Resmed ApneaLink Air device (Resmed, San Diego, CA).
Description: Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).

Intervention type: DIAGNOSTIC_TEST
Intervention: Resmed ApneaLink Air device (Resmed, San Diego, CA).
Description: Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
Study: NCT04561427

Intervention type: OTHER
Intervention: Study of Sleep architecture in children with narcolepsy
Description: Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children